- The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein 11 October 2021 Georgina C Girt
- Variation on a theme: mapping microglial heterogeneity 26 September 2021 Sam J Washer
- A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 23 September 2021 Jiandong Huo
- Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern 18 August 2021 Donal T Skelly
- Correlative multi-scale cryo-imaging unveils SARS-CoV-2 assembly and egress 31 July 2021 Luiza Mendonça
- Differentiation of human induced pluripotent stem cells to authentic macrophages using a defined, serum-free, open-source medium 25 June 2021 Alun Vaughan-Jackson
- Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism 28 May 2021 Justyna Okarmus
- Geographical distribution of fertility rates in 70 low-income, lower-middle-income, and upper-middle-income countries, 2010-16: a subnational analysis of cross-sectional surveys 21 May 2021 Carla Pezzulo
- Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism 20 May 2021 Joanne Ng
- Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers 30 April 2021 Björn F Vahsen
DPhil Student | firstname.lastname@example.org
Szymon is a DPhil student in Interdisciplinary Bioscience (BBSRC DTP in collaboration with Eli Lilly).
Neurodegenerative diseases, especially Alzheimer’s and Parkinson’s, affect millions of people worldwide. Unfortunately, there has been little to no success in developing treatments to prevent the onset or slow the progress of these diseases. Inflammation within the central nervous system can affect the course of neurodegenerative diseases, but – at the moment – we lack a representative human in vitro system to suitably mirror the neuroinflammatory state. Induced Pluripotent Stem Cells (iPSCs) can be generated from human donor skin or blood cells and turned into different brain cell types.
Szymon’s project will address the above limitation by culturing different human iPSC brain cell types together in a three-dimensional scaffold, including brain immune cells, microglia. This will enable us to study neuroinflammation and neurodegeneration ‘in a dish’. Szymon graduated from The University of Nottingham (MSci Neuroscience). During his studies, he developed an interest in cell culture models by working on in vitro conditions which could promote stem cell characteristics in cancer cells (thanks to Dr Dr. Androutsellis-Theotokis). During a placement year at the Alzheimer’s Research UK Drug Discovery Institute at University College London, he was focusing on culturing primary rat microglia in serum free conditions (thanks to Dr Lorenza Magno). When finishing off the time in Nottingham, his MSci thesis indicated that a polygenic risk score generated from microglial genes can partly predict the risk of developing Alzheimer’s disease (thanks to Prof Kevin Morgan).